Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy

Abstract

The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.

Role of homocysteine metabolism in the development of endothelial dysfunction and hypertension in patients with multiple myeloma

“…ЭД является ранним предиктором атеросклероза и будущих сердечно-сосудистых событий (табл. 1) [10]. Основными маркерами ЭД считают снижение синтеза эндотелиального NO, повышение уровней ЭТ-1, циркулирующего фактора Виллебранда, ингибитора активатора плазминогена, ГЦ, тромбомодулина, растворимой молекулы сосудис той межклеточной адгезии B1, С-реактивного белка, микроальбуминурию и др.…”